Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort

Although Fingolimod is registered as a second-line drug in relapsing-remittend multiple sclerosis (RRMS) in Europe there are no clinical studies available comparing Fingolimod (FTY) and Natalizumab (N). This observational cohort-study used health data routinely collected in outpatient neurology prac...

Descripción completa

Detalles Bibliográficos
Autores principales: Braune, Stefan, Lang, M., Bergmann, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843369/
https://www.ncbi.nlm.nih.gov/pubmed/24008757
http://dx.doi.org/10.1007/s00415-013-7082-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843369/
https://www.ncbi.nlm.nih.gov/pubmed/24008757
http://dx.doi.org/10.1007/s00415-013-7082-0

Ejemplares similares